Dr. Michael J. Manyak is Professor and Interim Chairman of the Department of Urology at The George Washington University Medical Center (GWUMC). Dr. Manyak is also Professor of Microbiology and Tropical Medicine at GWUMC. After Dr. Manyak completed his urological residency at GWUMC, he became an American Foundation For Urological Disease (AFUD) Scholar at the National Cancer Institute (NCI), completed a fellowship in biotechnology in 1988, and joined the urological staff at GWUMC. His research interests include the expression and regulation of a protein which inhibits metastasis, monoclonal antibody use for detection of prostate cancer metastasis, surgical simulation with virtual reality, and other applications of medical biotechnology.

Dr. Manyak was one of 70 physicians appointed to the Medicare Coverage Advisory Committee for the Health Care Finance Administration (HCFA) which determines Medicare reimbursement for all medical procedures and technologies. In addition to a presidential appointment to the National Kidney and Urological Disease Advisory Board, he has recently been appointed as a voting member of the FDA Regulatory Panel for Genitourinary and Gastrointestinal Devices. He has been a frequent reviewer for the NIH Special Study Section for Small Business Grants and several professional journals. Dr. Manyak served as Chairman of the AUA Technology Assessment Council and on 5 other national AUA Committees related to technology for 5 years. He has published over 150 professional abstracts, book chapters, and refereed journal articles, has been granted 10 patents with several pending, and is on the scientific advisory board or consultant to more than 25 biomedical technology companies. Dr. Manyak was profiled by the Washingtonian Magazine in December 2001 as one of 50 people selected as "The Best and Brightest of Washington." Family Urology Magazine also profiled Dr. Manyak in April 2003.

Dr. Manyak was the Managing Medical Editor of the nationally-acclaimed Time-Life Medical Publications prostate cancer educational video and the Medical Editor for the Public Broadcasting Corporation (PBS) video Check It Out which received both the Creative Excellence Award at the US International Film and Video Festival and a National Media Owl Award in 1997. He is a urologic consultant to Mens Health Magazine and a frequent media contact on behalf of the AUA. He has numerous appearances on national networks for CBS, NBC, Fox News, and CNN and has been the guest of John McLaughlin on One On One.

Dr. Manyak is a founder of Metastatin Pharmaceuticals, Inc., and is a founder and director of two health care companies, AdventureCare, Inc., for travel medical coverage in remote locations and MED-GARD, Inc., which provides charitable medical services in remote underserved areas. Dr. Manyak is a consultant to several journalists and members of the National Geographic Society, NPR Radio Expeditions, and USA Today for travel medical issues and is the urologic consultant to the Peace Corps.

Dr. Manyak maintains an avid interest in field exploration and expedition medicine. He was selected as a Fellow National of The Explorers Club in 1992, has chaired the Expeditions Committee since 1995, and was appointed to the Science Advisory Board in 1997 which he now chairs. He has served on The Explorers Club Board of Directors since 1996. His column on Expedition Medicine has appeared in the Explorers Journal. Since 1990 Dr. Manyak has been the Field Medical Advisor to the International Society of Cryptozoology (ISC) which investigates unknown or undescribed animals throughout the world. Dr. Manyak has led a scientific expedition to the Ndoki rain forest in the Congo Basin in a collaborative effort with the World Wildlife Fund, has dived the Spanish galleon Nuestra Senora de Atocha in search of artifacts, and was the medical director for the RMS Titanic salvage expedition in 2000 and dove to the Titanic wrecksite in the Russian MIR submersible.

Business Address:
The George Washington University Medical Faculty Associates
Department of Urology
2150 Pennsylvania Ave., N. W.
Washington, D. C. 2003
(202) 741-3100 office
(202) 741-3113 fax

PROFESSIONAL POSITIONS

PROFESSIONAL COMMITTEES AND SOCIETIES

NATIONAL

National Kidney and Urological Disease Advisory Board, 1992 -94

Special Subcommittee for formation of a National Urological Institute, 1992 -94
Health Care Issues Subcommittee, 1993 -94

Consultant to FDA Regulatory Panel for Gastrointestinal and Genitourinary Devices, 1991 -93; 2002-

Center for Medicare Services (CMS) Medicare Coverage Advisory Committee, 1999 -

Fellow, American College of Surgeons, 1992 -

American Urological Association National Committees

Technology Assessment Council (Chairman), 1995 -00
New Technology Assessment Committee, 1992 -00
Chairman, 1995 -00
Biomedical Engineering Committee, 1992 -94
Ad Hoc Laser Prostatectomy Committee, 1992 -94
Laser Committee, 1993 -00
Health Policy Survey and Research Committee, 1993 -97
Surgical Simulation Committee, 1996 -00
Molecular and Biological Technology Committee, 1996 -00
Terminology Committee, 1999 -02
Research Committee, Mid Atlantic Section rep 2002-

National Advisory Panel for Free Electron Laser National User Facility 1988 -90

Scientific Advisory Board:

InnerDyne Medical, Inc. 1990-
Advanced Surgical, Inc. 1992-96
Searle Laboratories 1993-95
GWUMC Biomed Engineering Institute 1995-
Imagyn, Inc. 1996-98
Debiopharm, Inc. (Chairman) 1996-00
Metastatin Pharmaceuticals, Inc. 1996-
GWUMC Lab Advanced Computer Applications in Med 1997-
Boston Scientific, Inc. 1997-
Urologix, Inc. 1997-99
ATI Medical, Inc. 1997-
ALZA Pharmaceuticals 1999-01
ENDOCare, Inc. 1999-
BioSafe, Inc. 2000-
GenomicsFund.com 2000-02
NorthPoint Domain, Inc. 2000-
Pacific Strategies and Assessments, Inc. 2000-
Imalux, Inc. 2001-
Bayer Pharmaceuticals 2001-
Sanofi-Synthelabo, Inc. 2002-
Pfizer, Inc. 2002-
Aventis 2003-

Mid-Atlantic Section Representative, Urological Political Action Committee (UROPAC) 1994-96
       American Association of Clinical Urologists

Consultant to:

C. R. Bard Urologic Div. 1993- Quadra Logic Technologies 1990-
Cytogen Corporation 1991- Schering-Plough, Inc. 1992-96
Ethicon, Inc. 1991-95 Trimedyne Corporation 1994-95
LaserscopeSurgical Systems 1991-96 Pharmacia Upjohn Inc. 1993-
Olympus Corporation 1991-96 ILEX Oncology, Inc. 2000-
Pfizer, Inc. 1994- Urologix, Inc. 2001-
Sanofi-Synthelabo, Inc. 2002-

NASA - Advanced Concepts and Technology 1994-
Walter Reed Army Medical Center 1991-

Men’s Health Magazine 1999-

American Urological Association Public Relations 1998-

REGIONAL

American Urological Association Mid-Atlantic Section Executive Committee 1994-97

Socioeconomic Committee 2000-02

Scientific Program Director, American Urological Association Mid-Atlantic Section Meeting 2002

Washington Urological Society Executive Committee
Nominating Committee Chairman 1992
Treasurer 1993
Secretary 1994
Vice President 1995
President 1996

The George Washington University Roundtable on Education 1998-99

The George Washington University Medical Center Task Force on Medical Center 1998-00
    Arrangements with Pharmaceutical or Medical Device Manufacturers

The George Washington University Laboratory for Computer Applications in Medicine 1995-

The George Washington University Medical School Admissions Committee 1988-90

The George Washington University Hospital:

Cancer Center Advisory Committee 1992-94
Committee on Medical Research 1992-94 Laser Committee 1989- Operating Room Committee 1991-92
Laparoscopy Committee 1992- Operating Room Design 1993-95
Faculty Practice Committee 1994-97
Medical Faculty Bylaws Committee 1994-95
Committee of Chairs 1995-
Executive Committee 1997-
Practice Standards Committee 1997-99
Public Relations Committee 1997-
Medical Director Committee of Chairs 1998-

CORPORATE

President and Founder, Center for Urologic Research and Education (CURE) [501 (c)3] 1991

Founder, Metastatin Pharmaceuticals, Inc. 1994-

Vice President and Founding Director, MED-GARD, Inc. [501 (c)3] 1999-

President and Founding Director, AdventureCare, Inc. 1999-

PROFESSIONAL SOCIETIES

EDITORIAL AND GRANT REVIEW ACTIVITIES

Editor, Laser Section, Techniques in Urology.

Urologic consultant, Mens Health Magazine.

Editorial Board, Clinical Prostate Cancer.

NIH Technology and Applied Sciences Review Section (1993-96). Reviewed 30-40 biotechnology grants quarterly.

American Foundation for Urology Disease Research Grant Review Committee 1993-94.

Consulting editor, Laparoscopic Urologic Surgery. Gomella LG, Kozminski MJ, Winfield HN (eds). Raven Press, NY,1993.

Associate Editor, 5 Minute Urology Consult: Gomella LG and Dambro M (eds). Williams and Wilkins, Philadelphia, 2000.

NON-PROFESSIONAL COMMITTEES AND SOCIETIES

Field Medical Advisor, International Society of Cryptozoology

The Explorers Club, Fellow National (92)

EXPEDITIONS

• Congo River Reconnaisance Expedition, April 15-30, 1996
  Expedition leader for site visit to Sanga-Dzanga Reserve in the Ndoki rain forest with National Geographic Explorer program and Anheuser-Busch wildlife film program. Feasibility of airship reconnaisance in Central African Republic.
  
  
• South African Rural Community Medical Site Visit, February 9-23, 1999
  Site visit director for assessment of existing medical facilities, supplies, and logistics for rural communities surrounding game reserves in Kwazulu-Natal Province, Republic of South Africa, in conjunction with Conservation Corporation Africa.
  
  
• RMS Titanic Scientific and Medical Expedition 2000, July 20-August 23, 2000
  Director of medical services for salvage expedition to Titanic wrecksite. Provided travel medical insurance, supplies, telemedical communication, and personnel for 50 members. Dove in Russian MIR submersible to Titanic site for recovery and archaeological registration of artifacts. Assisted in obtaining 3-dimensional imaging data of deepwater bioluminescent fauna. Assisted in feasibility study of blue light data transmission in aqueous environment at over 2 miles below ocean surface.
  

AWARDS

PATENTS

RESEARCH INTERESTS

Photodynamic therapy (PDT)
Treatment of benign and malignant conditions by photochemical interaction between a retained photosensitizer and absorbed light. Current clinical protocols include 1) PDT of recurrent superficial bladder carcinoma using diffusion media for light distribution and 2) fluorescent detection of bladder carcinoma with a different photosensitizer.

Expression and Regulation of Uteroglobin in the Genitourinary Tract
Biochemical investigation of the role of arachidonic acid metabolism regulation in metastasis of prostate and other cancers. Translational research collaboration with the Department of Pharmacology. Our results demonstrate a strong inhibitory effect on prostate cancer invasion and suggest that the gene may play a significant role in the natural progression of prostate cancer.

Radioimmunoscintigraphy for Detection of Prostate Cancer Metastasis
Detection of prostate carcinoma recurrence or metastasis by monoclonal antibodies. Current clinical protocols have accrued one of the largest series of patients in these multicenter studies for both recently diagnosed prostate cancer in patients at risk for metastasis and for patients with occult recurrent disease.

Laser Technology for Diagnosis and Treatment of Urological Disorders
Diagnostic and therapeutic applications of laser technology. This collaboration with researchers at the Biomedical Instrumentation and Engineering Branch at the National Institutes of Health and the Naval Research Laboratory is an extension of work over the past 10 years evaluating various diagnostic light modalities. Diagnostic uses of diffuse reflectance spectroscopy, fluorescence, optical coherent tomography, and laser Doppler effects are under evaluation for clinical application in conjunction with minimally-invasive access.

Surgical Simulation for Education
Use of virtual reality and surgical simulation of urological procedures. This collaboration is a major focus for the multidisciplinary Laboratory for Adanced Computer Applications in Medicine established in 1995 at GWU in conjunction with the School of Engineering and Applied Science.

SELECTED RECENT PROFESSIONAL ACTIVITIES

National Kidney and Urological Disease Advisory Board 4 year White House appointment 1992-96

Subcommittee on New Institute. One of 2 urologists on committee of 6 preparing recommendation to Congress for creation of new institute in the National Institutes of Health for kidney and urological disease.

Subcommittee Health Care Policy. Only urologist on committee of 3 preparing response to the Clinton administration health care reform recommendations as they pertain to kidney and urological disease.

Nominee to American Board of Urology, 1994.

Testimony to the U. S. House Subcommittee on Appropriations on behalf of the National Kidney and Urologic Disease Advisory Board. May 1993, April 1994, May 1994.

Invited participant and presenter on laser diagnostic technology at the NASA Office of Advanced Concepts and Technology workshop entitled Future Capabilities and Requirements in Space Biosensors. This workshop concerned advanced biotelemetry and biosensor data acquisition methods for future NASA priorities. May 1994.

Director and Chairman:

• American Society for Lasers in Surgery and Medicine. Urology Section. 1993-1994.
  
• American Urological Association Biomedical Engineering Forum on Lasers. AUA National Meeting, San Antonio, TX, 1993.
  
• American Urological Association Biomedical Engineering Forum on Teleurology: Advances in Information and Diagnostic Systems . AUA National Meeting, Orlando, FL 1996.
  
• American Urological Association Biomedical Engineering Forum on Biomechanical Applications of Thermal Extremes in the Prostate. AUA National Meeting, New Orleans, LA 1997.
  
• American Urological Association Biotechnology Forum on Voiding Dysfunction: Etiology and Advances in Treatment. AUA National Meeting, San Diego, CA 1998.
  
• American Urological Association Biotechnology Forum on Molecular Biological Technology. AUA National Meeting, Dallas, TX 1999.
  
• American Urological Association Biotechnology Forum on Medical Imaging Technology. AUA National Meeting, Atlanta, GA 2000.
  

Urologic consultant to the NIH multicenter study Medical Treatment of Prostate Symptoms. NIH grant # 1 UO1 DK46472-01. 1994 to present.

Principal investigator:

• Photodynamic Therapy of Superficial Bladder Carcinoma. Collaboration with Radiobiology Branch, National Cancer Institute.
  
• Benign Prostatic Hyperplasia Treatment Outcome Pilot Study. Sponsored by the American Urological Association.
  
• Multicenter Study of Intravenously Administered 111In-Cyt-356 in the Evaluation of Patients Prior to Staging Pelvic Lymph Node Dissection. Cytogen Corporation.
  
• Multicenter Study of Intravenous Doses of 111In-Cyt-356 in the Detection of Occult Prostate Carcinoma. Cytogen Corporation.
  
• Phase II Study of Oral Bropirimine in Adult Patients with BCG-Resistant Bladder Carcinoma in Situ. Pharmacia Upjohn.
  
• Virtual Reality Surgical Simulation for Cryotherapy of Prostate Carcinoma. EndoCare, Inc.
  
• Phase I/II Dose Escalation Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Transurethral Photodynamic Therapy with QLT0074 for Benign Prostatic Hyperplasia. IRB# 120211
  
• A national phase II trial of Intron, interferon-alfa 2b Plus BCG for treatment of superficial bladder cancer. IRB#019908
  
• Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer. IRB# 010109
  
• Study of the Diagnostic Efficacy of Optical Coherence Tomography in the Management of Superficial Bladder Cancer.
  
• Prostate Tissue and Hormone Study, a methodologic study. IRB#089913ER
  
• Phase III randomized, double-blind study of DFMO vs placebo in low grade superficial bladder cancer. IRB#019901
  
• Co-principal investigator: Exploratory/Developmental Grants for Diagnostic Cancer Imaging. NIH RO1 submission.

Course Director:

Circon-ACMI PG Course. Surgical Use of Lasers.
GWU Medical Center PG Course. Lasers: Present and Future in Urology.
GWU Medical Center PG Course. Endoscopic Laparoscopy.
14th World Congress of Endourology. Photodynamic Therapy for Urology.

Instructor/Preceptor for industrial representatives:
Merck, Sharp, & Dohme. Health Science Liaison Representatives.
TAP Pharmaceuticals. National training center for laparoscopic surgery.
C. R. Bard Urological Division. Marketing representative training.
Cytogen Corporation Sales representative training.

Moderator for podium or poster session:
Mid-Atlantic AUA Section Annual Meeting 1990, 1992-93, 1995-03
AUA Annual Meeting 1992, 1994-03
World Congress of Endourology 1997-00

Organizing Committee: 16th World Congress of Endourology, New York, NY. 1998.
17th World Congress of Endourology, Rhodes, Greece. 1999.

Program Director Mid-Atlantic American Urological Association Annual Meeting, Baltimore, MD. 2002.

Invited speaker (Last 3 years):

2001

• Minnesota Urological Association Annual Meeting. Microwave thermotherapy for Benign Prostatic Hyperplasia. Minneapolis, MN.
  
• First International Prostate Cancer Congress. Uteroglobin: A Novel Tumor Suppressor with Antiangiogenic Properties. San Juan, Puerto Rico.
  
• First International Prostate Cancer Congress. Imaging Prostate Cancer: From Molecules to Application. San Juan, Puerto Rico.
  
• Health Network America Prostate Cancer Symposium. New Technologies and Biomarkers to Detect Prostate Cancer. Panama City, Panama.
  
• Health Network America Prostate Cancer Symposium. Imaging Prostate Cancer. Panama City, Panama.
  
• Health Network America Prostate Cancer Symposium. New Therapies and Future Research for Prostate Cancer. Panama City, Panama.
  
• Houston Urological Society Meeting. Diving the Titanic: Tales of Medicine and Science from the North Atlantic. Houston, TX.
  
• Baylor College of Medicine Grand Rounds. Uteroglobin: A New Tumor Suppressor with Anti-angiogenic and Anti-Metastatic Properties. Houston, TX.

2002

• Beth Israel Grand Rounds. Uteroglobin: A New Tumor Suppressor with Anti-angiogenic and Anti-Metastatic Properties.
  
• Eli Lilly Pharmaceuticals, Inc. The Clinical Role of Uteroglobin for Prostate and Other Cancers. Indianapolis, IN.
  
• Expedition Medicine Seminar: Minimizing Risk in the Field. General Organization of Medical Components on Expeditions: From Immunizations to Insurance. New York, NY.
  
• Expedition Medicine Seminar: Minimizing Risk in the Field. Tropical Medical Problems. New York, NY.
  
• Pfizer Science Advisory Board. Diving the Titanic: Tales of Medicine and Science from the North Atlantic. White Sulphur Springs, VA.
  
• Sanofi-Synthelabo Pharmaceuticals Reception. The RMS Titanic Salvage Expedition. Orlando, FL.
  
• American Urological Association Annual Meeting. Optical Coherence Tomography. Orlando, FL.
  
• American Urological Association Annual Meeting. Development of a Cryotherapy Simulator for Localized Prostate Cancer. Orlando, FL.
  
• National Youth Leadership Foundation on Medicine. Expedition Medicine. Washington, DC.
  
• Second International Prostate Cancer Congress. Imaging Prostate Cancer: New Molecules to New Applications. St. Thomas, Virgin Islands.
  
• Recent Advances in the Management of Prostate Cancer Conference. Panelist for management decisions. Washington, DC.
  
• International Urology Network. Advances in Diagnosis and Treatment of Prostate Cancer. Marina del Rey, CA.
  
• 10th Innovations in Urologic Practice. Innovative Imaging Technologies for Prostate and Urinary Tract. Santa Fe, NM.
  
• Urologic Laparoscopy: A Hands-On Practical Approach. AUA sponsored course. Basic Instrumentation and Operative Set-up. Baltimore, MD.
  
• Myeloma and Lymphoma 2002 Conference. Diving the Titanic: Tales of Medicine and Science from the North Atlantic. New York, NY.
  
• Mid-Atlantic American Urological Association Annual Meeting. Uteroglobin as Potential Prostate Cancer Tumor Suppressor with Anti-Invasive and Anti-Angiogenic Properties. Baltimore, MD.
  
• Mid-Atlantic American Urological Association Annual Meeting. Advances in Diagnostic Imaging. Optical Coherence Tomography. Baltimore, MD.
  
• Exploring New Alternatives in LHRH Therapy National Teleconference. Washington, DC.
  
• Trelstar Science Advisory Board Meeting. Advances in Diagnosis and Treatment of Prostate Cancer. Marina del Rey, CA.
  
• New Perspectives in Prostate Cancer Cancer 9th Symposium. Prostate Cancer 2002: The Year in Review. Washington, DC.
  
• New Perspectives in Prostate Cancer Cancer 9th Symposium. Imaging Prostate Cancer: New Molecules to New Techniques. Washington, DC.
  
• Medical Knowledge Forums in Urology. Understanding the Role of PSA as a Marker for BPH. Washington, DC.
  
• American Association of Philippine Physicians. Advances in Diagnosis and Treatment of Prostate Cancer. Baltimore, MD.

2003

• Conducted 4 national teleconferences on use of new LHRH agonist therapy for prostate cancer.
  
• National satellite media tour in NY with Harry Belafonte regarding prostate cancer education. New York, NY. 21 live interviews.
  
• Benign Prostatic Hyperplasia: Diagnosis and Management. Medicine Grand Rounds GW Hospital. Washington, DC.
  
• Advances in Medical Management of BPH. Regional urological meeting. Jacksonville, FL.
  
• PriMed Conference. Diagnosis and Management of BPH. Melville, NY.
  
• Diagnosis and Management of Bladder Cancer. Community lecture. GW Hospital. Washington, DC.
  
• Advances in Medical Management of BPH. Northern VA Nurse Practitioner Association. Fairfax, VA.
  
• Advances in Diagnosis and Treatment of Prostate Cancer. Grand Rounds. Hartford Hospital. Hartford, CT.
  
• Diagnosis and Management of BPH: Advances in Medical Management. Society of Urologic Nurses National Meeting. San Antonio, TX.
  
• Cooled Microwave Thermotherapy for BPH. Regional urological meeting. Philadelphia, PA.
  
• Management of BPH: Advances in Diagnosis and Treatment. Society of Urological Nurses Association. Rochester, MN.
  
• Diagnosis and Management of BPH: Medical Advances. Washington, DC.
  
• Medical Problems in Adventure Racing. International Society of Travel Medicine. Plenary session invited speaker. New York, NY.
  
• Advances in Medical Management of BPH. Regional urological meeting. Atlanta, GA.
  
• Plumbing the Depths: From Viagra to the Titanic. Walter Reed Army Medical Center. Washington, DC.
  
• Advances in Imaging Technology for Prostate Cancer. GW Prostate Cancer Support Group. Washington, DC.
  
• The Evolution of BPH and its Management. Regional urological meeting. Washington, DC.
  
• Third International Prostate Cancer Congress. Imaging Prostate Cancer: State-of-the-Art. Bermuda.

BOOKS

1. Manyak MJ, Nochomovitz LE: Cystoscopy and bladder biopsy: indications and technique. In:
   Bladder Biopsy Interpretations. Nochomovitz LE (ed). Raven Press, NY, pp 1-9, 1992.
2. Manyak MJ: Photodynamic therapy: basic principles and urologic applications. In: Lasers In Urologic
   Surgery. Smith JA, Stein BS, Benson RC (eds). Mosby-Year Book, Inc., Chicago, pp 230-257, 1993.
3. Manyak MJ, Scherr DS: Endoscopic management of bladder calculi and tumors. In: Textbook of
   Endourology. Sosa RE (ed). W B Saunders Co, Philadelphia, pp 236-250, 1996.
4. Manyak MJ: Endoscopic future perspectives: light as a diagnostic tool. In: Textbook of Endourology. Sosa RE (ed). W B Saunders Co, Philadelphia, pp 206-214, 1996.
5. Manyak MJ: The genetic basis of urologic malignancy. In: Current Genitourinary Cancer Surgery.
   Crawford ED, Das S (eds). Lea & Febiger, Philadelphia, pp 843-858, 1996.
6. Manyak MJ, Koota DH: Prostatism and Prostate Cancer. In: Ambulatory Geriatric Care. Yoshikawa TT, Cobbs EL, Brummel-Smith K (eds). Mosby-Year Book, Inc., Chicago, pp 202-210, 1998.
7. Geib KS, Manyak MJ: Adrenal Adenoma. In: 5 Minute Urology Consult. Gomella LG, Dambro M (eds). Williams and Wilkins, Inc., Philadelphia, pp 192-193, 2000.
8. Geib KS, Manyak MJ: Renal and Perirenal Abscess. In: 5 Minute Urology Consult. Gomella LG,
   Dambro M (eds). Williams and Wilkins, Inc., Philadelphia, pp 446-447, 2000.
9. Ogan K, Manyak MJ: Epididymitis/Orchitis. In: 5 Minute Urology Consult. Gomella LG, Dambro M
   (eds). Williams and Wilkins, Inc., Philadelphia, pp 280-281, 2000.
10. Ogan K, Manyak MJ: Condyloma Acuminata. In: 5 Minute Urology Consult. Gomella LG, Dambro M
    (eds). Williams and Wilkins, Inc., Philadelphia, pp 254-255, 2000.
11. Manyak MJ: Prostate Cancer, Metastatic (N+, M+). In: 5 Minute Urology Consult. Gomella LG,
    Dambro M (eds). Williams and Wilkins, Inc., Philadelphia, pp 414-417, 2000.
12. Debruyne FMJ, Djavan B, De La Rosette J, Desgrandchamps F, Fourcade RO, Gibbons RP, Kaplan SA, Hartung R, Krane RJ, Manyak MJ, Mebust WK, Muschter R. Murai M, Schulman CC, Sedelaar JPM,
    Stein BS, Teillac P, Zlotta AR: Interventional Therapy for Benign Prostatic Hyperplasia. In: Benign
    Prostatic Hyperplasia. Proceedings of the 5th International Consultation on Benign Prostatic
    Hyperplasia (BPH). Chatelain C, Denis L, Foo KT, Khoury S, McConnell JD (eds). Plymbridge
    Distributors, Ltd., Plymouth, UK, pp 397-423, 2001.
13. Manyak MJ: Advances In Biotechnology and Health Care. In: America’s New Vision: Our Leaders
    Point the Way. McCoy, DL (ed). 1st Books Library Publishers, Bloomington, IN, pp 352-353, 2002.
14. Manyak MJ, Santangelo K, Hahn J, Kaufman R, Carleton T, Hua XC, Walsh RJ: Virtual Reality Surgical
    Simulation for Lower Urinary Tract Endourologic Surgery. In: Bladder Disease: Research Concepts
    and Clinical Applications. Atala A (ed). Plenum Publishing Corp., New York ( in press).
15. Manyak MJ, Warner JW: Lasers in Urologic Surgery. In: Glenn’s Urologic Surgery . Kavoussi, LR (ed). (in press).
    

INSTRUCTIONAL VIDEOTAPES

Photodynamic Therapy for Urologic Malignancies. Laserscope, Inc., national instructional video.

Radioimmunoscintigraphy for Prostate Carcinoma with ProstaScint. Nuclear medicine instructional video.

Cooled Microwave Thermotherapy. Video news release. Urologix, Inc.

PSA Self-Collection Program for Prostate Cancer Screening. Video news release. BioSafe, Inc.

ABSTRACTS

1. Manyak MJ, Hill MC, Sacks H, Fialk G: The role of ultrasonography in evaluation of acute flank pain and colic. Presented at the 43rd Annual Meeting of the American Urological Association Mid-Atlantic Section. Philadelphia, October 4, 1985.

2. Manyak MJ, Matthews DM, Smith PD, Nochomovitz LE, Russo A: Photodynamic therapy: response of normal canine urethra using a cylindrical fiber. Presented at the Clayton Conference on PhotodynamicTherapy. Los Angeles, February18, 1987.

3. Manyak MJ, Matthews DM, Smith PD, Nochomovitz LE, Glatstein E, Russo A: Response of normal canine ureter to photodynamic therapy using a cylindrical fiber. Presented at the 82nd Annual Meeting of the American Urological Association. Anaheim, California, May 20, 1987.

4. Manyak MJ, Kikukawa T, Mukherjee AB: Expression of uteroglobin-like protein in human prostate. Presented at the American College of Surgeons 73rd Annual Clinical Congress, Surgical Forum - Reproductive Biology and Related Endocrinology. San Francisco, October 12, 1987.

5. Manyak MJ, Kikukawa T, Mukherjee AB: Uteroglobin-like protein in human prostate: possible role in infertility and inflammation. Presented at the 83rd Annual Meeting of the American Urological Association. Boston, June 4, 1988.

6. Manyak MJ, Solomon D, Nelson LM, Stillman RJ, Glatstein E: Vascular survival in normal rabbit muscular tissue after photodynamic therapy. Presented at the International Conference on Photodynamic Therapy and Medical Laser Applications. London, July 21, 1988.

7. Manyak MJ, Smith PD, Steinberg SM, Harrington FS, Glatstein E: Protection against dihematoporphyrin ether photosensitivity. Presented at the International Conference on Photodynamic Therapy and Medical Laser Applications. London, July 21, 1988.

8. Manyak MJ, Solomon D, Glatstein E: Photodynamic therapy of human prostate cancer using an interstitial cylindrical fiber in a murine model. Presented at the 46th Annual Meeting of the American Urological Association Mid-Atlantic Section. Baltimore, September 28, 1988.

9. Manyak MJ, Nelson LM, Solomon D, Thomas G, Russo A, and Stillman RJ: Photodynamic therapy of rabbit endometrial transplants: a model for treatment of endometriosis. Presented at the International Society for Optical Engineering Conference on Photodynamic Therapy: Mechanisms. Los Angeles, January 19, 1989.

10. Manyak MJ, Kondo T, DeGraff W, Pass HI, and Glatstein E: Fluorescent detection and chemical extraction of dihematoporphyrin ether from human prostate cancer in a murine model. Presented at the 84th Annual Meeting of the American Urological Association. Dallas, May 8, 1989.

11. Manyak MJ, Kondo T, Solomon D, DeGraff W, Thomas G, and Glatstein E: Photodynamic therapy of human prostate cancer: fluorescent detection, chemical extraction, and interstitial treatment in a murine model. Presented at the Photodynamic Therapy Workshop at the American Society for Photobiology 1989 Annual Meeting. Boston, July 2, 1989.

12. Manyak MJ, Cole JW, Thomas GF, and Smith PD: Laser optical fibers and the use of diffusion medium in bladder photodynamic therapy. Presented at the 47th Annual Meeting of the Mid-Atlantic Section of the American Urological Society. Munich, September 19, 1989.

13. Manyak MJ: The National Free Electron Laser User Facility: Implications for Urologic Research. Presented at the 10th Annual Meeting of the American Society of Lasers in Medicine and Surgery. Nashville, April 8, 1990.

14. Manyak MJ, Cole JW, and Smith PD: Whole bladder photodynamic therapy: enhancement of light distribution from laser optical fibers through use of diffusion medium. Presented at the 85th Annual Meeting of the American Urological Association. New Orleans, May 14, 1990.

15. Manyak MJ, Cole JW, and Smith PD: Light distribution and the use of diffusion medium for whole bladder photodynamic therapy. Presented at the Second Annual Greater Washington Urological Basic Science Research Seminar. Washington, D. C. June 7, 1990.

16. Manyak MJ, Nelson LM, Solomon D, DeGraff W, Stillman RJ, and Russo A: Fluorescent detection of rabbit endometrial implants created from monodispersed viable cell suspensions. Presented at the American Society for Photobiology 18th Annual Meeting. Vancouver, BC, June 17, 1990.

17. Manyak MJ, Kondo T, De Graff W, Glatstein E: Fluorescent detection, chemical extraction, and photodynamic therapy of human prostate cancer in a murine model. Presented at the 3rd Biennial Meeting of the International Photodynamic Association. Buffalo, NY, July 21, 1990.

18. Manyak MJ: Clinical use of whole bladder photodynamic therapy using a diffusion medium. Presented at the 48th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Richmond, September 16, 1990.

19. Manyak MJ, Mc Nellis RJ, Cole JW, and Smith PD: Clinical use of diffusion medium for whole bladder photodynamic therapy. Presented at the American Society for Photobiology 19th Annual Meeting. San Antonio, TX, June 26, 1991.

20. Manyak MJ, Cole JW, Smith PD, McNellis RJ: Whole bladder photodynamic therapy with intravesical diffusion medium: preliminary results. Presented at the 49th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Southampton, Bermuda, October 13, 1991.

21. Manyak MJ, Ahlgren JD, McNellis RJ, Lynne J, Yu GW, Myers CE: Treatment of hormone resistant metastatic prostate carcinoma with continuous infusion of suramin. Presented at the 87 th Annual Meeting of the American Urological Association. Washington, DC, May 12, 1992.

22. Manyak MJ, Cole JW, McNellis RJ, Smith PD: Downstaging of BCG-resistant carcinoma in situ of the bladder by photodynamic therapy with intravesical diffusion medium. Presented at the 87 th Annual Meeting of the American Urological Association. Washington, DC, May 13, 1992.

23. Manyak MJ, Cole JW, McNellis RJ, Smith PD: Downstaging of BCG-resistant carcinoma in situ of the bladder by whole bladder photodynamic therapy using diffusion medium: preliminary results. Presented at the 4th Biennial Meeting of the International Photodynamic Association, Milan, Italy, June 27, 1992.

24. Manyak MJ, Ahlgren JD, McNellis RJ, Lynne J, Yu GW, Myers CE: Cumulative dose-related suramin toxicity in patients with hormone refractive metastatic prostate carcinoma. Presented at the 50th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Williamsburg, VA, September 22, 1992.

25. Chung S, Zook BC, Scher D, Manyak MJ: The effects of hyperthermia on canine bladder. Presented at the 50th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Williamsburg, VA, September 22, 1992.

26. Ochadlik MN, Manyak MJ, Miller HC, Semerjian HS, McAfee J: Detection of metastatic or recurrent prostate adenocarcinoma with radiolabeled murine IgG1 antibody. Presented at the MD Anderson Cancer Center Genitourinary Oncology Conference: The Clinical Implications of Prostate Cancer Biology. Houston, TX, February 12, 1993.

27. Manyak MJ, Cole JW, McNellis RJ, Smith PD: Photodynamic therapy with intravesical diffusion medium for BCG-resistant carcinoma in situ of the bladder. Presented at the 13th Annual Meeting of the American Society for Lasers in Medicine and Surgery. New Orleans, LA, April 18, 1993.

28. Gomella LG, Lotfi MA, Stone NN, Sosa RE, Schichman S, Albala D, Manyak MJ, Kozminski M: Laparoscopic urologic surgery: improvement in outcome. Presented at the 88 th Annual Meeting of the American Urological Association. San Antonio, TX, May 15, 1993.

29. Manyak MJ, Cole JW, McNellis RJ, Smith PD: Treatment of BCG-resistant carcinoma in situ of the bladder. Presented at the 11th International Medical Convention of the National Arab American Medical Association. Amman, Jordan, June 24, 1993.September 22, 1992.

30. Ochadlik MN, Manyak MJ, Miller HC, Semerjian HS, Varma V, McAfee J: Monoclonal antibody immunoscintigraphy for the detection of metastatic and recurrent prostate adenocarcinoma. Presented at the 51st Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Palm Beach, FL, September 20, 1993.

31. Manyak MJ: Urologic applications of laser technology. Presented at the 1993 Lasers and Electro- Optics Society Annual Meeting. San Jose, CA, November 16, 1993.

32. Manyak MJ, Leyton J, Patierno SR, Miele L, Mantile G, Mukherjee AB: Uteroglobin Inhibition of Prostate Carcinoma Invasion. Presented at the Schering National Speakers Update Symposium, Naples, FL. Feb 26, 1994.

33. Manyak MJ, Sacknoff EJ: Laser applications in urology. Presented at 14th Annual Meeting of the 1994 American Society of Lasers in Medicine and Surgery. Toronto, Canada, April 8, 1994.

34. Leyton J, Manyak MJ, Mukherjee AB, Miele L, Mantile G, Patierno SR: Recombinant human uteroglobin-like protein (cc10 kDa) inhibits the chemoinvasive activity of DU 145 human prostate tumor cells in vitro: correlation with inhibition of arachidonic acid release. Presented at the American Association of Cancer Research Annual Meeting. Proceedings of the American Association of Cancer Research, Vol 35, abstr # 1675. San Francisco, CA, April 11, 1994.

35. Manyak MJ, Leyton J, Patierno SR, Mantile G, Miele L, Mukherjee AB: Inhibition of prostate adenocarcinoma invasion in vitro by uteroglobin. Presented at the 89 th Annual Meeting of the American Urological Association. San Francisco, CA, May 16, 1994.

36. Manyak MJ, Aulisi GP, Smith PD, Russo A: Treatment outcomes of photodynamic therapy with diffusion medium for BCG-resistant bladder carcinoma. Presented at the 5th International Photodynamic Association Biennial Meeting. Amelia Island, FL, September 19, 1994.

37. Manyak MJ, Leyton J, Patierno SR, Mantile G, Miele L, Mukherjee AB: Inhibition of prostate adenocarcinoma invasion in vitro by recombinant human uteroglobin. Presented at the 52nd Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Philadelphia, PA, September 24, 1994.

38. Manyak MJ, Aulisi GP, Marks M, McAfee J: Laparoscopic confirmation of metastatic prostate adenocarcinoma detected by monoclonal antibody radioimmunoscintigraphy. Presented at the 52nd Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Philadelphia, PA, September 24, 1994.

39. Manyak MJ, Aulisi GP, Ochadlik MN, Marks M, McAfee J: The role of laparoscopy for confirmation of metastatic prostate adenocarcinoma detected by monoclonal antibody radioimmunoscintigraphy. Presented at the Society of Laparoscopic Surgeons Annual Meeting. Orlando, FL, December 6, 1994.

40. Patierno SR, Weeraratna AT, Leyton J, Mukherjee AB, Manyak MJ: Loss of uteroglobin expression in invasive prostate adenocarcinoma cell lines: reconstitution with recombinant human uteroglobin inhibits in vitro invasiveness. Presented at the Basic and Clinical Aspects of Prostate Cancer (an American Association of Cancer Research special conference). Palm Springs, CA, Dec 8, 1994.

41. Weeraratna AT, Leyton J, Loden GB, Mukherjee AB, Manyak MJ, Patierno SR: Loss of uteroglobin expression in metastatic human prostate cancer cell lines. Presented at the American Association of Cancer Research Annual Meeting. Proceedings of the American Association of Cancer Research, Vol 36, abstr #453. Toronto, Canada, March 22, 1995.

42. Gomella LG, Taha A-M, Hirsch IH, Albala D, Manyak MJ, Richardson W, Kozminski M, Sosa RE, Stone NR: Laparoscopic urologic surgery: continued improvement in outcome. Presented at the 90th Annual Meeting of the American Urological Association. Las Vegas, NV, April 25, 1995.

43. Burgers JK, Hinkle G, Badalament RA, Babaian R J, Podoloff D, Texter J, Neal C, Libertino J, Seldin D, Manyak MJ, Marks M, Lange P, Nelp W, McGuire R: Multicenter study of prostate cancer lymph node imaging with 111 IN Capromab Pendetide. Presented at the 90th Annual Meeting of the American Urological Association. Las Vegas, NV, April 26, 1995.

44. Manyak MJ, Leyton J, Loden GB, Miele L, Mantile G, Mukherjee AB, Patierno SR: Uteroglobin inhibition of prostate adenocarcinoma invasion in vitro: a new class of tumor suppresson genes? Presented at the 90th Annual Meeting of the American Urological Association. Las Vegas, NV, April 27, 1995.

45. Manyak MJ, Aulisi GP, Smith PD, Russo A: Photodynamic therapy with diffusion medium for BCG- resistant bladder carcinoma. Presented at the 1995 Annual Meeting of the British Association of Urologic Surgeons. Brighton, Great Britain, June 19, 1995.

46. Manyak MJ, Leyton J, Loden GB, Miele L, Mantile G, Mukherjee AB, Patierno SR: Uteroglobin inhibition of prostate adenocarcinoma invasion in vitro. Presented at the 1995 Annual Meeting of the British Association of Urologic Surgeons. Brighton, Great Britain, June 19, 1995.

47. Enquist EG, Granovsky M, Miller HC, Manyak MJ: A comparison of outcomes of standard electro- resection prostatectomy, laser prostatectomy, and Vaportrode prostatectomy. Presented at the 53rd Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Southampton, Bermuda, September 17, 1995.

48. Sokas RK, Moline JM, Ryan M, Manyak MJ, Bar-Chama N, Landrigan PJ: Depressed testosterone levels among five cadmium-exposed workers. Presented at the 123rd Annual Meeting of the American Public Health Association.

49. Manyak MJ, Aulisi GP, Smith PD, Russo A: The role of photodynamic therapy in management of superficial bladder carcinoma. Presented at the International Photodynamic Association Biennial Meeting. Melbourne, Australia, March 11, 1996.

50. Weeraratna AT, Cajigas JA, Ghafoorian R, Manyak MJ, Patierno SJ: Analysis of uteroglobin expression in benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), prostate cancer (PC), prostate lymph node metastases, and metastatic prostate tumor cell lines. Presented at the American Association of Clinical Research 87th Annual Meeting. Washington, DC, April 21, 1996.

51. Weeraratna AT, Leyton J, Cajigas JA, Schwartz AJ, Manyak MJ, Patierno SR: Loss of uteroglobin expression in metastatic human prostate cancer. Presented at the Society for Basic Urological Research 1996 Annual Meeting. Orlando, FL, May 3, 1996.

52. Enquist EG, Granovsky M, Miller HC, Manyak MJ: A comparison of short-term effects of transurethral resection, laser procedures, and electrovaporization of the prostate. Presented at the 91st Annual Meeting of the American Urological Association. Orlando, FL, May 7, 1996.

53. Enquist EG, Manyak MJ, Singh I, Miller HC: A comparison of transurethral electroresection, laser procedures, and electrovaporization of the prostate - one year follow up. Presented at the 54th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Washington, DC, October 29, 1997.

54. Weeraratna AT, Cajigas JA, Schwartz AJ, Enquist EG, Manyak MJ, Patierno SR: Loss of uteroglobin expressionin prostate cancer (PC), a prostate cancer lymph node metastasis and metastatic prostate cancer tumour cell lines: positive expression in prostatic intraepithelial neoplasia (PIN) may be a molecular marker which differentiates PIN from cancer. Presented at the 54th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Washington, DC, October 28, 1997.

55. Andrawis RI, Cortino J, Lindquist R, Albertsen PC, Manyak MJ, Kreutzer DL: Cytokine regulation in angiogenesis of human bladder cancer. Presented at the 54th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Washington, DC, October 28, 1997.

56. Weeraratna AT, Cajigas JA, Schwartz AJ, Manyak MJ, Patierno SR: Loss of uteroglobin expression in metastatic human prostate cancer. Presented at annual meeting of the Society of Experimental Biology and Medicine, March 13, 1997.

57. Chiachierni RP, Piantadosi S, Partin AW, Burgers JK, Libertino JA, Texter JH, Manyak MJ, Meyer J, Maguire RT: Logistic regression analysis combining results of serum PSA, Gleason score, and monoclonal antibody scan (ProstaScint) to predict lymph node involvement in clinically localized prostate cancer. Presented at the 92nd Annual Meeting of the American Urological Association. New Orleans, LA , April 13, 1997.

58. Andrawis RI, Contrino J, Lindquist RL, Albertsen PC, Manyak MJ, Kreutzer DL: Interleukin-8 expression and human bladder cancer: in -situ and in-vitro expression of IL-8 by human bladder cancer cells. Presented at the 92nd Annual Meeting of the American Urological Association. New Orleans, LA , April 14, 1997.

59. Weeraratna AT, Attiga FA, Manyak MJ, Patierno SR: Aberrant transcription and translation of uteroglobin in human prostate cancer. Presented at the the American Association of Clinical Research 88th Annual Meeting. San Diego, CA, April 16, 1997.

60. Manyak MJ, Khati NJ, Marks MA, Feeney E, Javitt MC: Comparison of ProstaScint with cross sectional imaging for detection of metastatic adenocarcinoma of the prostate gland. Presented at the Society of Urologic Radiology Annual Meeting. Santa Fe, NM, June 14, 1997.

61. Andrawis RI, Nashid NS, Albertsen PC, Walzak MP, Manyak MJ, Kreutzer DL: Angiogenesis index and outcomes of radical prostatectomy. Presented at the 55th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Hot Springs, VA, September 16, 1997.

62. Manyak MJ, Weeraratna AT, Schwartz AJ, Enquist EG, Patierno SR: Loss of uteroglobin (Clara cell 10kD protein) expression correlates with higher Gleason score in human prostate cancer specimens. Presented at the 55th Annual Meeting of the Mid-Atlantic Section of the American Urological Assoc. Hot Springs, VA, September 16, 1997.

63. Coetzee LJE, Manyak MJ, Schall R, Grosgurin P, Porchet HC: Effectiveness of new 1-month sustained release formulation of Triptorelin to induce a chemical castration with a complete inhibition of LH and FSH secretion. Presented at the XXII Biennial Congress of the Urological Association of South Africa. Cape Town, RSA, March 4, 1998.

64. Andrawis RI, Nashid NS, Windham CT, Albertsen PC, Walzak MP, Manyak MJ, Kreutzer DL: Blood vessel density (angiogenesis index) and outcomes in radical prostatectomy. Presented at the 93rd Annual Meeting of the American Urological Association. San Diego, CA, June 3, 1998.

65. Manyak MJ, Weeraratna AT, Schwartz AJ, Enquist EG, Patierno SR: Loss of uteroglobin expression correlates with higher grade human prostate cancer. Submitted to the 93rd Annual Meeting of the American Urological Association.

66. Manyak MJ, Ackerman SJ, Blute ML, Rein AL, Beusterien K, Sullivan EM, Tanio CP, Strauss MJ: Cost-effectiveness of microwave thermal therapy in patients with benign prostatic hyperplasia. Presented at the 93rd Annual Meeting of the American Urological Association. San Diego, CA,
June 3, 1998.

67. Polascik TJ, Gurganus RT, Partin AW, Rogers B, Maguire RT, Manyak MJ: Comparison of staging algorithms and a monoclonal antibody scan (ProstaScint) to predict lymph node involvement in high- risk prostate cancer. Presented at the 93rd Annual Meeting of the American Urological Association. San Diego, CA, June 3, 1998.

68. Ackerman SJ, Beusterien K, Blute ML, Rein AL, Sullivan EM, Tanio CP, Hanson KA, Kerr RA, Strauss MJ, Manyak MJ: Cost-utility of microwave thermal therapy in patients with benign prostatic hyperplasia. Presented at the 6th Annual Symposium on Quality of Life Evaluation. Hilton Head, SC, March 28, 1999.

69. Fernandez PM, Walsh CJ, Veyrune JL, Pattaras JG, Schwartz AM, Manyak MJ, Patierno SR: Development of a prostate cancer growth and metastasis model. Presented at the American Association of Clinical Research 90th Annual Meeting. Philadelphia, April 10-14, 1999.

70. Attiga FA, Fernandez PM, Manyak MJ, Patierno SR: Inhibition of human prostate tumor cell invasion through a reconstituted basement membrane by the cyclooxygenase-2-selective inhibitor NS398. Presented at the American Association of Clinical Research 90th Annual Meeting. Philadelphia, April 10-14, 1999.

71. Hahn J, Kaufman R, Carleton T, Hua XC, Manyak MJ, Walsh RJ: Virtual reality surgical simulation for lower urinary tract endourologic surgery. Presented at the 94th Annual Meeting of the American Urological Association. Dallas, TX, May 1-4, 1999.

72. Walsh CJ, Scarzella GI, Hamid NIA, Manyak MJ: Reduced post operative infection rates and increased patient satisfaction following Ambicor penile prosthesis insertion. Presented at the 57th Annual Meeting of the Mid-Atlantic Section of the American Urological Assoc. Hilton Head, SC, October 3-6, 1999.

73. Walsh CJ, Geib KS, Fernandez PM, Patierno SR, Manyak MJ: Development of an avian in vivo assay for the study of human prostate cancer progression. Presented at the 57th Annual Meeting of the Mid-Atlantic Section of the American Urological Assoc. Hilton Head, SC, October 3-6, 1999.

74. Attiga FA, Fernandez PM, Manyak MJ, Patierno SR: Effect of the cyclooxygenase-2-selective inhibitor NS398 on the secretion of matrix metalloproteinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) from human prostate tumor cells. Presented at the American Association of Clinical Research 91st Annual Meeting. San Francisco, CA, April 1-5, 2000.

75. Manyak MJ, Fernandez PM, Walsh CJ, Gieb KS, Goldberg GS, Schwartz AM, Patierno SR: Development of an avian in vivo assay for human prostate cancer growth and metastasis. Submitted to the 95th Annual Meeting of the American Urological Association. Atlanta, GA, April 29-May 4, 2000.

76. Manyak MJ, Ackerman SJ, Rein AR, Beusterien K, Tanio CP, Sullivan MJ, Strauss MJ, Blute ML: Cost effectiveness of treatment for benign prostatic hyperplasia (BPH): an economic model for comparison of medical, minimally-invasive, and surgical therapy. Presented at the 18th World Congress of Endourology. Sao Paolo, Brazil, September 15, 2000.

77. Manyak MJ, Hahn J, Kaufman R, Carleton T, Hua XC, Walsh RJ: Virtual reality surgical simulation for lower urinary tract endourological procedures. Presented at the 18th World Congress of Endourology. Sao Paolo, Brazil, September 16, 2000.

78. Ogan K, Manyak MJ: Long term clinical outcomes of single treatment photodynamic therapy (PDT) with intravesical diffusion medium for refractory superficial bladder cancer. Presented at the 58th Annual Meeting of the Mid-Atlantic Section of the American Urological Association. Rio Grande, Puerto Rico, October 18, 2000.

79. Manyak MJ, Hinkle GH, Partin AW, Chiacchierini RP, Piantadosi S, Olsen J: Radioimmunoscintigraphy for prostate cancer. Presented at the 25th Congress of the Societe Internationale d’ Urologie. Singapore, October 31, 2000.

80. Manyak MJ, Fernandez PM, Weeraratna A, Pattaras JG, Geib KS, Walsh CJ, Goldberg G, Schwartz AM, Patierno SR: Uteroglobin: a potential tumor suppressor with antiangiogenic properties. Presented at the 2nd Annual Meeting of the Society of Urological Oncology. Bethesda, MD, December 1, 2001.

81. Szlyk GR, Fernandez PM, Manyak MJ, Patierno SR: Ibuprofen inhibits angiogenesis in the rat aorta and endothelial tubule-forming assays. Presented at the 2nd Annual Meeting of the Society of Urological Oncology. Bethesda, MD, December 1, 2001.

82. Manyak MJ, Hahn JK, Jin G, Kim D, Rewcastle J, Kim S, Walsh RJ: Cryotherapy simulator for localized prostate cancer. Presented at the 97th Annual Meeting of the American Urological Association. Orlando, FL, May 25, 2002.

83. Fernandez PM, Szlyk GR, Attiga FA, Mandel G, Schwartz AM, Manyak MJ, Patierno SR: Effects of NSAIDS on angiogenesis and prostate tumor growth. Presented at the American Association of Cancer Research 93rd Annual Meeting. . Proceedings of the AACR, Volume 43, 2nd ed., May 2002. San Francisco, CA, April 6-10, 2002.

84. Manyak MJ, Fernandez PM, Szlyk GR, Schwartz AM, Patierno SR: Uteroglobin as potential prostate cancer tumor suppressor with anti-invasive and anti-angiogenic properties. Presented at the 60th Annual Meeting of the Mid-Atlantic Section of the American Urological Assoc. Baltimore, MD, Oct 9, 2002.

85. Sovell CK, Fernandez PM, MJ, Patierno SR. Cytostatic effects of chronic recombinant human uteroglobin on prostate tumor cells: growth inhibition leads to apoptotic cell death. Proceedings of the AACR, Volume 44, 2nd ed., July 2003. Presented at the American Association of Cancer Research 94th Annual Meeting. Washington, DC, July 12, 2003.

86. Manyak MJ. Imaging Prostate Cancer: State-of-the- Art. Presented at the Third International Prostate Cancer Congress. Bermuda, July 17, 2003.

PUBLICATIONS

1. Manyak MJ: Cancer incidence in the United States and the Philippines. Phil J Int Med 17(2): 104-111, 1979. Asian Med J, April 1979.

2. Manyak MJ, Frensilli FJ, Miller HC: 2,8 - Dihydroxyadenine urolithiasis: report of an adult case in the
United States. J Urol 137: 312-314, 1987.

3. Manyak MJ, Harrington FJ, Glatstein E: A cystoscope holder/surgical retractor that really works. J Urol 138: 105-106, 1987.

4. Manyak MJ, Matthews DM, Smith PD, Nochomovitz LE, Glatstein E, Russo A: Response of normal
canine ureter to photodynamic therapy using a cylindrical fiber. J Urol 139: 199-203, 1988.

5. Manyak MJ, Russo A, Glatstein E: Photodynamic therapy. J Clin Oncology 6 (2): 380-391, 1988.

6. Manyak MJ, Smith PD, Harrington FS, Steinberg SM, Glatstein E, Russo A: Protection against
dihematoporphyrin ether photosensitivity. Photochem Photobiol 47(6): 823-830, 1988.

7. Manyak MJ, Matthews DM, Smith PD, Nochomovitz LE, Russo A: Photodynamic therapy: response
of normal canine urethra using a cylindrical fiber. Lasers Surg Med 8 (3): 301-307, 1988.

8. Manyak MJ, Kikukawa T, Mukherjee AB: Expression of uteroglobin-like protein in human prostate. J
Urol 140: 176-182, 1988.

9. Manyak MJ, Nelson LM, Solomon D, Thomas G, Russo A, Stillman RJ: Photodynamic therapy of rabbit endometrial transplants: a model for treatment of endometriosis. Fertil Steril 52: 140-145, 1989.

10. Manyak MJ: Photodynamic therapy: present concepts and future applications. The Cancer Journal
3 (2): 104-109, 1990.

11. Manyak MJ, Nelson LM, Solomon D, DeGraff W, Stillman RJ, Russo A: Fluorescent detection of rabbit endometrial implants resulting from monodispersed viable cell suspensions. Fertil Steril 54: 356-359, 1990.

12. Tochner Z, Mitchell JB, Hoekstra HJ, Smith PD, DeLuca AM, Barnes M, Harrington FS, Manyak MJ,
Russo D, Russo A: Photodynamic therapy of the canine peritoneum: normal tissue response to IP
and IV Photofrin followed by 630 nm light. Lasers Surg Med 11: 158-164, 1991.

13. Manyak MJ: Benign enlargement of the prostate (BPH): what it is . . . what can be done about it.
Retirement Life: 44-46, May 1991.

14. Manyak MJ: Photodynamic therapy: principles and urological applications. In: Laser Use in Urology
(Manyak MJ ed). Sem Urol 9 (3): 192-202, 1991.

15. Selman SR, Manyak MJ: Future use of lasers in urology. In: Laser Use in Urology (Manyak MJ ed).
Sem Urol 9 (3): 210-213, 1991.

16. Manyak MJ: Treatment options for prostate problems. Retirement Life: 22-23, June 1991.

17. Manyak MJ: Pharmacologic treatment for benign prostatic hyperplasia. Drug Therapy : 44-52,
Dec.1991.

18. Manyak MJ: PDT for superficial bladder cancer: aspects of light distribution. Urology Times 20 (1): 7-
10, 1992.

19. Manyak MJ: Photodynamic therapy: principles and practices in urology. Problems in Urology 6: 399-
413, 1992.

20. Manyak MJ: Pharmacologic treatment for benign prostatic hyperplasia. Phys Asst J 16: 103-107,1992.

21. Ochadlik MN, Karmi SA, Manyak MJ, Miller HC: Clinical uroradiology conference: a seventy-eight year
old man with flank pain. Urology 39: 569-572, 1992.

22. Manyak MJ: The light at the end of the tunnel: one view of laparoscopic future. Sem Urol 10(4): 205-
212, 1992.

23. Manyak MJ: Photodynamic therapy for superficial bladder carcinoma. Current Opinion in Urology 3:
220-229, 1993.

24. Salem Y, Pagliaro LC, Manyak MJ: Primary small non-cleaved cell lymphoma of the kidney. Urology
42: 331-335, 1993.

25. Manyak MJ: Urological applications of laser technology. Proceedings Laser Electro Optical Society
(IEEE) 1993: 242-243, 1993.

26. Leyton J, Manyak MJ, Mukherjee AB, Miele L, Mantile G, Patierno SR: Recombinant human
uteroglobin inhibits the in vitro invasiveness of human metastatic prostate tumor cells and the release
of arachidonic acid stimulated by fibroblast-conditioned medium. Cancer Res 54: 3696-3699, 1994.

27. Manyak MJ: The clinical relevance of gene therapy. This week in Investigative Urology. J Urol 152:
292-293, 1994.

28. Greifer I, Diamond LH, Jacobson H, Knox F, Manyak MJ, Marver DH, Menon M, O'Brien Jackson ML:
Proposal to establish a national institute of kidney and urological diseases. Report of the National
Kidney and Urological Diseases Advisory Board. J Urol 152: 485-490, 1994.

29. Manyak MJ: Photodynamic therapy for urologic malignancies. AUA Update 12: 94-104, 1995.

30. Manyak MJ, Aulisi GP: Free beam and contact laser ablation of benign prostatic hyperplasia with the
KTP/Nd:YAG laser: efficacy and versatility. World J Urol 13: 104-108, 1995.

31. Gee WF, Holtgrewe HL, Albertsen PC, Litwin M, Manyak MJ, O'Leary MP, Painter MR: Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States. J Urol 154:
205-206, 1995.

32. Gee WF, Holtgrewe HL, Albertsen PC, Litwin M, Manyak MJ, O'Leary MP, Painter MR: Practice trends in the diagnosis and management of prostate cancer in the United States. J Urol 154: 207-208, 1995.

33. Manyak MJ: The practical aspects of photodynamic therapy for superficial bladder cancer. Techniques Urol 1: 84-93, 1995.

34. Manyak MJ: An evolving approach to the surgical management of superficial bladder carcinoma. Surg Technol Internat 4: 271-282, 1995.

35. Manyak MJ: Bladder cancer: the good, the bad, and the ugly. J Urol 155: 103-104, 1996.

36. Manyak MJ: Local recurrence of prostate cancer: dilemma for physician and patient. Family Urol: 10-
18, Spring 1996.

37. Gee WF, Holtgrewe HL, Albertsen PC, Litwin MS, Manyak MJ, O'Leary MP, Painter MR, Blizzard RT,
Fenninger RB, Emmons L: Practice trends of American urologists in the treatment of impotence,
incontinence, and infertility. J Urol 156: 1778-1780, 1996.

38. Strauss MJ, Khanna V, Koenig JD, Downs SM, Goldberg SH, Manyak MJ, Patsner B: The cost of
treating genital warts. Int J Derm 35: 346-348, 1996.

39. Manyak MJ: Advances in imaging prostate cancer. Advances in Prostate Cancer Monographs1 (3):
5-7, 1997.

40. Gomella LG, Meguid-Abdel TA, Lotfi MA, Hirsch IH, Albala DM, Manyak MJ, Kozminski M, Sosa RE,
Stone NN: Laparoscopic urologic surgery: continued improvement in outcome. J Laparos Surg 7: 77- 86,
1997.

41. Weeraratna AT, Cajigas JA, Schwartz AJ, Enquist EG, Manyak MJ, Patierno SR: Loss of uteroglobin
expression in prostate cancer: relationship to advancing grade. Clin Cancer Res 3: 2295-2300, 1997.

42. Chiacchierini RP, Piantadosi S, Partin AW, Burgers JK, Libertino JA, Texter JH, Manyak MJ, Maguire
RT: Logistic regression analysis combining serum PSA, Gleason score and monoclonal antibody scan
(ProstaScint) to predict lymph nodal involvement in prostate cancer. J Urol 157: 205, 1997.

43. Bruskewitz RC, Fourcade R, Koshiba K, Manyak MJ, Pisani E, Resel Estez L, Vincente Rodriguez J:
Interventional therapy: surgery. Proceedings of the 4th International Consultation on Benign
Prostatic Hyperplasia (BPH) 4: 523-528, 1997.

44. Gee WF, Holtgrewe HL, Albertsen PC, Cooper TP, Fenninger RB, Litwin MS, Manyak MJ, Meyer JJ, Miles BJ, O'Leary MP, Painter MR, Rohner TJ, Thomas R, Blizzard RT, Emmons L: Subspecialization, recruitment, and retirement trends of American urologists. J Urol 159: 509-511, 1998.

45. Sarosdy MF, Manyak MJ, Sagalowsky AI, Belldegrun A, Benson MC, Bihrle W, Carroll PC, Ellis WJ, Hudson MA, Sharkey FE: Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology 51; 226-231, 1998.

46. Heller KN, Manyak MJ, Tabbara SO, Kerr LA: Malignant osteoclast-like giant cell tumor of the kidney. Urology 51: 495-498, 1998.

47. Manyak, MJ: Clinical Overview and AUA Perspective: Assessing the New Technology. In: Prostate Disease. Evolution in Technology and Its Impact on Treatment. Kaplan SA (ed). Monograph for Continuing Medical Education, College of Physicians and Surgeons of Columbia University: 1-5, 1998.

48. Manyak MJ, Javitt MC: The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. Sem Urol Oncol 16: 145-152, 1998.

49. Kahn D, Williams RD, Manyak MJ, Haseman MK,Seldin DW, Libertino JA, Maguire RT: 111 In- capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer following radical prostatectomy. J Urol 159: 2041-2047, 1998.

50. Manyak MJ: Clinical applications of radioimmunoscintigraphy with prostate specific antibodies for prostate cancer. Cancer Control 5: 493-499, 1998.

51. Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, Partin AW: Comparison of clinical staging algorithms and In-capromab pendetide immunoscintigraphy to predict lymph node involvement in high-risk prostate cancer patients. Cancer 85: 1586-1592, 1999.

52. Manyak MJ, Hinkle GH, Chiacchierini RP, Piantadosi S, Partin AW, Olsen J, Burgers JK, Texter JH Jr.,
Neal CE, Maguire RT: Immunoscintigraphy with 111 In-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. Urology 54: 1058-1063, 1999.

53. Manyak MJ: Expedition medicine: are you prepared? Explorers Journal 77: 6-7, 1999.

54. Manyak MJ: Capromab pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging. Cancer Biother and Radiopharm 15: 127-130, 2000.

55. Attiga FA, Fernandez PM, Weeraratna A, Manyak MJ, Patierno SR: Inhibitors of prostaglandin synthesis inhibit human prostgate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Research 60: 4629-4637, 2000.

56. Ackerman SJ, Rein AL, Blute ML, Buesterien K, Sullivan EM, Tanio CP, Manyak MJ, Strauss MJ: Cost-effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia : part I - methods. Urology 56: 972-980, 2000.

57. Blute ML, Ackerman SJ, Rein AL, Buesterien K, Sullivan EM, Tanio CP, Strauss MJ, Manyak MJ:
Cost-effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia : part II - results. Urology 56: 981-987, 2000.

58. Debruyne FMJ, Djavan B, De La Rosette J, Desgrandechamps F, Fourcade R, Gibbon R, Kaplan S,
Hartung R, Krane R, Manyak MJ, Mebust W, Muschter R, Murai M, Schulman CC, Sedelaar JPM, Stein
BS, Teillac P, Zlotta A: Interventional therapy for benign prostatic hypertrophy. Proceedings of the
5th International Consultation on Benign Prostatic Hyperplasia (BPH) 5: 397-422, 2000 .

59. Rosenblatt GS, Schneidau TA, Walsh CJ, Manyak MJ: Anastomotic calculus formation after side-to- side ureteroureterostomy in complete ureteral duplication. J Urol 164:1644-1645, 2000.

60. Manyak MJ: RMS Titanic scientific and medical expedition 2000. BAUS Today 2: 42-43, 2001.

61. Manyak MJ, Macedonia CR, Morley DT: Science and medicine on the high seas. Explorers Journal 79 (1): 24-25, 2001.

62. Manyak MJ: Solving enigma of prostate cancer takes varied paths. Editorial. Urology Times 29 (5): 2, 2001.

63. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR: Inhibition of prostaglandin synthesis inhibits human prostate tumor cell invasiveness and reduces the release of matrix metalloproteinases. Cancer Res 60: 4629-4637, 2001.

64. Chou DS, Manyak MJ: The enigma of prostatitis. ADVANCE for Nurse Prac 9: 63-70, 2001.

65. Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E: A comparison of urinary nuclear matrix protein 22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. Br J Urol Int 88: 692-701, 2001.

66. Manyak MJ: Medicine for the outdoors: the essential guide to emergency medical procedures and first aid. Book review. Explorers Journal 79 (3): 39, 2002.

67. Manyak MJ, Ackerman SJ, Blute ML, Rein AL, Buesterien K, Sullivan EM, Tanio CP, Strauss MJ: Cost effectiveness of treatment for benign prostatic hyperplasia: an economic model for comparison of medical, minimally-invasive, and surgical therapy. J Endourol 16: 51-56, 2002.

68. Manyak MJ, Santangelo K, Hahn J, Kaufman R, Carleton T, Hua X C, Walsh RJ: Virtual reality surgical simulation for lower urinary tract endoscopy and procedures. J Endourol 16: 185-190, 2002.

69. Szlyk GR, Rosenblatt GS, Manyak MJ: Current perspectives of imaging in diagnosis and managment of bladder malignancy in women. J Womens Imaging 4: 58-65, 2002.

70. Patierno SR, Manyak MJ, Fernandez PM, Baker A, Weeraratna AT, Chou DS, Szlyk GR, Geib KS, Walsh CJ, Pattaras JG. Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostrate cancer. Clin Prostate CA 1: 118-124, 2002.

71. Nasir A, Copeland J, Gillespie JW, Chugtai OR, Andrawis RO, Manyak MJ: Pre-neoplastic lesions of the prostate – clinical, pathologic and molecular biological aspects. In Vivo: 16(6): 557-66, 2002.

72. Manyak MJ: Down, down to the Titanic. Notre Dame Magazine 31: 44-46, 2003.

73. Manyak MJ, Ogan K: Photodynamic therapy for refractive bladder cancer: long term outcomes of single treatment using diffusion medium. J Endourol (in press).

74. Manyak MJ, Warner JW: An update on laser use in urology. Contemporary Urol (in press).

75. Williams SB, Szlyk GR, Manyak MJ: Leiomyoma of the urinary bladder (submitted for publication).

76. Williams SB, Szlyk GR, Manyak MJ: Metastatic malignant peripheral nerve sheath tumor of the kidney (submitted for publication).